Navigation Links
PDL BioPharma to Announce First Quarter 2010 Financial Results and Hold Conference Call on April 29, 2010
Date:4/22/2010

INCLINE VILLAGE, Nev., April 22 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that the Company will hold a conference call and webcast on Thursday, April 29 at 4:30 p.m. Eastern Time to discuss its financial results for the first quarter 2010. The call and webcast will follow the release of the first quarter financial results after market close.

Conference Call Details

To access the live conference call via phone, please dial (800) 688-0836 from the United States and Canada or (617) 614-4072 internationally. The conference ID is 10899707. Please dial in approximately ten minutes prior to the start of the call. A telephone replay will be available beginning approximately one hour after the call through April 30, 2010, and may be accessed by dialing (888) 286-8010 from the United States and Canada or (617) 801-6888 internationally. The replay passcode is 55966470.

To access the live and subsequently archived webcast of the conference call, go to the Company's website at http://www.pdl.com and go to "Company Presentations & Events." Please connect to the website at least 15 minutes prior to the call to allow for any software download that may be necessary.

About PDL BioPharma

PDL pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases. PDL is focused on maximizing the value of its antibody humanization patents and related assets. The Company receives royalties on sales of a number of humanized antibody products marketed today based on patents which expire in late 2014. For more information, please visit www.pdl.com.

NOTE: PDL BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc.


'/>"/>
SOURCE PDL BioPharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. PDL BioPharma Announces Fourth Quarter and Full Year 2009 Financial Results and Provides First Quarter 2010 Revenue Guidance
2. ClearTrial Launches New Service to Bring Speed and Accuracy in Clinical Trial Planning Within Reach of Smaller Biopharma Companies
3. Indiana Biopharmaceutical Service Providers Maintain Steady Growth Despite Industry Challenges
4. SynCo Bio Partners Signs New Manufacturing Agreements to Supply the US Market; Securing its Position as a Market Leader in Microbial Biopharmaceutical Contract Production
5. ClearTrial to Demonstrate Dramatic Gains in Clinical Outsourcing Efficiency Achieved by Biopharmaceutical Companies at European Outsourcing Event
6. Sinobiopharma Announces Second Quarter 2010 Financial Results
7. Microbix And Therapure Biopharma Form Partnership To Expand Water-Based Supplies To The Pharma Industry
8. YM BioSciences Inc. and Therapure Biopharma Inc. Announce Contract
9. Array BioPharma and Amgen Partner in Type 2 Diabetes
10. PDL BioPharma Provides Fourth Quarter 2009 Revenue Guidance of Approximately $57 Million
11. PDL BioPharma Announces Ex-Dividend Date of November 27 for Special Dividend
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... Calif. , Jan. 17, 2017  Protagonist ... announced that it has initiated a global Phase ... an oral peptide that targets alpha4beta7 integrin. The ... study is to evaluate the safety/tolerability and efficacy ... patients with moderate to severe active disease. ...
(Date:1/16/2017)...   Valentin A. Pavlov, PhD , associate investigator, ... CEO of The Feinstein Institute for Medical Research ... the nervous system regulates the immune system, which will ... devices to treat disease and injury. The analysis ... The paper examines various studies which further define ...
(Date:1/14/2017)... ... January 14, 2017 , ... Seattle-based Phase ... end-to-end genome assemblies to researchers around the globe. Long considered a “holy ... answering a wide range of scientific questions. The announcement was made today ...
(Date:1/13/2017)... and Markets has announced the addition of the "Global Biopolymers Market ... ... 16.83% during the period 2017-2021. The report covers the ... 2017-2021. To calculate the market size, the report considers the revenue generated ... a a discussion of the key vendors operating in this market. ...
Breaking Biology Technology:
(Date:1/4/2017)... of attendees at this year,s International Consumer Electronics Show (CES), A&D ... and services, will be featuring its new line of ULTRA CONNECT ... CES Exhibit Suite , the new upper arm and wrist smart blood ... product platform.  Continue Reading ... ...
(Date:12/20/2016)... , Dec. 20, 2016 The ... sharing, rental and leasing is stoking significant interest ... radio frequency technology, Bluetooth low energy (BLE), biometrics ... as the next wave of wireless technologies in ... access system to advanced access systems opens the ...
(Date:12/16/2016)... The global wearable medical device market, in terms of value, is ... billion in 2016, at a CAGR of 18.0% during the forecast ... Growth ... devices, launch of a growing number of smartphone-based healthcare apps compatible ... and increasing focus on physical fitness. Furthermore, growing ...
Breaking Biology News(10 mins):